Exp Mol Med 2008,
PMID: 18985009
Kim, Ja Eun; Kim, Hong Sook; Shin, Yong Jae; Lee, Chang Seok; Won, Cheolhee; Lee, Sin Ae; Lee, Jung Weon; Kim, Youngsoo; Kang, Jae Seung; Ye, Sang Kyu; Chung, Myung Hee
Tumor migration/invasion is the main cause of tumor progression and STAT3 is needed to enhance tumor migration/invasion by up-regulating MMP-9. Thus, agents that inhibit STAT3 activation may be used as an anticancer drug. We present herein that 6-methyl-2-propylimino-6, 7-dihydro-5H-benzo [1, 3]-oxathiol- 4-one (LYR71) , a derivative of trimeric resveratrol, has an anticancer activity through inhibition of STAT3 activation. We found that LYR71 suppressed STAT3 activation and inhibited the expression and activity of MMP-9 in RANTES-stimulated breast cancer cells. In addition, LYR71 reduced RANTES-induced MMP-9 transcripts by blocking STAT3 recruitment, dissociating p300 and deacetylating histone H3 and H4 on the MMP-9 promoter. Furthermore, LYR71 inhibited tumor migration/invasion in RANTES-treated breast cancer cells and consequently blocked tumor progression in tumor-bearing mice. Taken together, the results of this study suggest that LYR71 can be therapeutically useful due to the inhibition effect of STAT3-mediated MMP-9 expression in breast cancer cells.
Diseases/Pathways annotated by Medline MESH: Breast Neoplasms, Mammary Neoplasms, Experimental
Document information provided by NCBI PubMed
Text Mining Data
STAT3 ⊣ MMP-9: "
We found that LYR71 suppressed
STAT3 activation and
inhibited the expression and activity of
MMP-9 in RANTES stimulated breast cancer cells
"
MMP-9 → STAT3: "
Taken together, the results of this study suggest that LYR71 can be therapeutically useful due to the inhibition effect of STAT3 mediated MMP-9 expression in breast cancer cells
"
Manually curated Databases
No curated data.